english.prescrire.org > Spotlight > 100 most recent > Prescrire's drug ratings in 2025: a brief review

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's drug ratings in 2025: a brief review

 Marketing Authorisations  2025 saw 3 major therapeutic advances for children, and a few other notable advances. Compared with previous years, just as many drugs offered no advantages over existing treatment options, and slightly more drugs were more dangerous than beneficial. In several cases, new data on previously evaluated drugs changed their harm-benefit balance.
Full article available for download (FREE)

Prescrire's ratings of new products and indications over the past 10 years
 
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Bravo  BRAVO
0 0 0 0 1 0 0 0 0 1
A Real Advance  A REAL ADVANCE
1 1 2 1 2 3 0 0 0 2
Offers an advantage  OFFERS AN ADVANTAGE
5 9 11 10 6 14 11 10 6 9
Possibly helpful  POSSIBLY HELPFUL 
9 18 22 13 18 19 23 20 23 21
Nothing new  NOTHING NEW
56 45 50 61 55 51 63 73 60 60
Judgement reserved  JUDGEMENT RESERVED
5 4 5 9 17 12 13 10 14 4
Not acceptable  NOT ACCEPTABLE 
16 15 9 14 10 9 14 8 18 22
TOTAL 92 92 99 108 109 108 124 121 122 119
 
 
Therapeutic advances 2012-2021
 

 

©Prescrire 1 April 2026

Source: "Prescrire's drug ratings in 2025: a brief review" Prescrire Int 2026; 35 (280): 101-103. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 

"Towards better
patient care:
drugs to avoid in 2026"
Prescrire Int 2026;
35 (278): 54-55
(full version: 12 pages).
FREE
 

"Prescrire's ratings
of new drugs in 2024:
a brief review"
Prescrire Int 2025;
34 (269): 102-104.
FREE